What is Myriad Genetics Inc (MYGN) stock price today?

Myriad Genetics Inc (MYGN) currently trades at $4.11 per share. The stock has a market capitalization of $475.05M and a P/E ratio of —x.

Is MYGN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Myriad Genetics Inc has a Smart Value Score of 44/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -0.01.

What is Myriad Genetics Inc's revenue and earnings?

Myriad Genetics Inc has trailing twelve-month (TTM) revenue of $557.00M with profit margins of -41.30%. Earnings per share (EPS) is $-4.31.

Is Myriad Genetics Inc financially healthy?

Myriad Genetics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -0.01 places it in the distress.

MYGN

Myriad Genetics Inc

NASDAQ: MYGN · HEALTHCARE · DIAGNOSTICS & RESEARCH

$4.11

-18.29% today

Updated 2026-05-06

Market cap

$475.05M

P/E ratio

—

P/S ratio

0.85x

EPS (TTM)

$-4.31

Dividend yield

—

52W range

$4 – $9

Volume

1.9M

Market cap

$475.05M

P/E ratio

—

P/S ratio

0.85x

EPS (TTM)

$-4.31

Dividend yield

—

52W range

$4 – $9

Volume

1.9M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

4.0

Growth

5.0

Quality

C+

2.0

Profitability

5.3

Valuation

C+

3/9

Piotroski F-Score

Weak

-0.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →197 stocks currently score above 75

Price targets

Analyst target

$7.42

+80.54%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy1 Buy7 Hold1 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths

+ Free cash flow $4.60M — positive

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -0.01 — distress zone

- Thin margins at -41.30%

- Revenue declining -20.80% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$678.40M	$753.20M	$837.60M	$824.50M	$557.00M
Net income	$-112.00M	$-263.30M	$-127.30M	$-365.90M	$-7.90M
EPS	—	—	—	—	$-4.31
Free cash flow	$-151.60M	$-184.20M	$-38.40M	$-25.60M	$4.60M
Profit margin	-16.51%	-34.96%	-15.20%	-44.38%	-41.30%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-14	VERRATTI, MARK	Sale	1,069	$4.91
2026-04-14	MUZZEY, DALE	Sale	946	$4.91
2026-03-22	WHEELER, BENJAMIN RICHARD	Sale	549	$4.58

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MYGN	$475.05M	44	4.0	2.0	5.3	5.0	—	Hold
LLY	$862.01B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$546.90B	59	4.7	9.0	3.3	6.0	-40.34%	Buy
ABBV	$365.43B	63	4.0	8.0	4.0	5.0	-22.55%	Buy
UNH	$336.72B	54	5.3	5.5	7.3	4.8	+43.12%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+3.99%	Buy

Smart narrative

Myriad Genetics Inc trades at $4.11. Our Smart Value Score of 44/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -0.01, it sits in the distress. TTM revenue stands at $557.00M. with profit margins at -41.30%.

Frequently asked questions

What is Myriad Genetics Inc's stock price?

Myriad Genetics Inc (MYGN) trades at $4.11.

Is Myriad Genetics Inc overvalued?

Smart Value Score 44/100 (Grade D, Sell).

What is the price target of Myriad Genetics Inc (MYGN)?

The analyst target price is $7.42, representing +80.5% upside from the current price of $4.11.

What is Myriad Genetics Inc's revenue?

TTM revenue is $557.00M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-0.01 — distress.

Company info

SectorHEALTHCARE

IndustryDIAGNOSTICS & RESEARCH

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.myriad.com

Quick metrics

P/S ratio0.85x

ROE-23.50%

Beta1.64

50D MA$4.78

200D MA$6.04

Shares out0.09B

Float0.09B

Short ratio—

Avg volume1.9M

Performance

1 week-0.83%

1 month+1.05%

3 months-10.11%

YTD-21.95%

1 year—

3 years—

5 years—

Compare

MYGN vs LLY →MYGN vs JNJ →MYGN vs ABBV →Stock screener →